



We are pleased to announce that the QIBA MSK Biomarker Committee has released its **QIBA MR-based cartilage compositional biomarkers (T1 $\rho$ , T2) for risk prediction, early diagnosis and monitoring of treatment of degenerative joint disease Profile** for a 90-day Public Comment period that will end on Tuesday, September 29, 2020.

The Public Comment Phase of the development of each QIBA Profile allows interested people to provide input on the Profiles, the scenarios and use cases they address, the technologies proposed and other details. In particular, vendors that will implement the Profiles and members of the health care community who will use the Profiles are encouraged to review and comment.

- The MSK Profile and public comment form (containing submission instructions) are available on the [Profiles Wiki page](#) directly under the heading **Stage 1: Public Comment Profiles**
- Please email [qiba@rsna.org](mailto:qiba@rsna.org) with any questions about the public comment submission process

The QIBA MSK Biomarker Committee will consider all comments submitted in the designated public comment period. Please feel free to forward this request to colleagues. Thank you for your support and participation.

**QIBA MSK Biomarker Committee Leaders:**

Xiaojuan Li, PhD (Co-chair)

Thomas Link, MD, PhD (Co-Chair)